URL has been copied successfully!
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.
Analysts expect the Wilmington, Delaware-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals’ quarterly revenue is $19.43 million, according to Benzinga Pro.
On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.
NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.
Benzinga readers can access the latest analyst ratings on …
Please follow us:
This post was originally published here
